New treatment for children with hard-to-treat retinoblastoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial focuses on patients with refractory retinoblastoma, a serious eye cancer in children. It aims to evaluate the effectiveness of targeting NUDT21 siRNA drugs, which may enhance anti-tumor activity while minimizing side effects compared to traditional chemotherapy. The study includes patients with specific genetic mutations and active tumors who wish to preserve their eyes despite previous treatments failing. The trial is conducted at the Eye & ENT Hospital of Fudan University in Shanghai.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients with retinoblastoma with a somatic mutation of the gene RB1 and active tumor in a single eye, or germinal mutation of RB1 with active tumor/s in an eye and the contralateral eye unaffected, enucleated or without tumor activity. In both cases, relapsed or refractory with the use of systemic, intraarterial or intravitreal chemotherapy or radiotherapy, in accordance with the availability at his/her referral site, in whom enucleation is the only recommended treatment under opinion of the medical team treating the case at the originating referral site. But the patient has a strong desire to preserve the eye.
2. Normal renal function: serum creatinine: \< 45 μmol/L (0-2 years); \< 57 μmol/L (3-6 years); \< 60 μmol/L (7-10 years); \< 80 μmol/L (11-13 years).
3. Normal Hepatic function: serum ALT: \< 0,52 μkat/L (de 9 months -12 years); serum AST: 61-80 g/L (8 months - 5 years); 63-83 g/L (5-9 years); 63-82 g/L (9-12 years).
4. Age greater than 6 months at the time of inclusion in the study.
5. Sign the informed consent form and be willing to follow up at the specified time.

Exclusion Criteria:

1. Presence of factors that require immediate enucleation of the affected eye such as glaucoma, rubeosis iridis, anterior chamber involvement.
2. Comorbidities: Uncontrolled epilepsy with anticonvulsant treatment, cardiac disease not compensated by treatment.
3. Active Infections.
4. Other chronic or active acute diseases that under the criterion of the researcher were an exclusion criterion.
5. History of having received attenuated or live vaccines in the 30 days prior to inclusion in the study.
6. Any cause of Immunosuppression.
7. Trilateral Retinoblastoma.
8. Extraocular spread.
9. History of having received treatment for retinoblastoma with chemotherapy or radiation therapy by any means within 30 days prior to inclusion in the study.
10. Patients who can not complete the study procedures.

Where it's running

• Fudan Eye & ENT Hospital
  Shanghai, China Recruiting

Study contacts

• Principal investigator: Chen Zhao, MD — Fudan Eye & ENT Hospital
• Study coordinator: Chen Zhao, MD
• Email: dr_zhaochen@fudan.edu.cn
• Phone: 86-021-64377134

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Intratumoral DNX-2401 for High-Grade Pediatric Brain Tumors

  This study tests whether a single injection of DNX-2401 into a pediatric brain tumor can help shrink the tumor and extend survival in kids and young adults with recurrent or refractory high-grade brain tumors.

  Recruiting Phase 2 Clinica Universidad de Navarra, Universidad de Navarra · Utrecht and 1 other locations · NCT07424092

• Micropulse laser treatment for new and refractory center-involved diabetic macular edema

  This project will test whether a subthreshold 577 nm micropulse laser helps adults with new or treatment-resistant center-involved diabetic macular edema reduce retinal swelling and improve vision.

  Recruiting The General Authority for Teaching Hospitals and Institutes · Cairo · NCT07295704

• Daratumumab for refractory aplastic anemia in adults

  This trial tests whether daratumumab can be safely given and help people with refractory aplastic anemia see a benefit.

  Recruiting Phase 1/2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07287228

• xDRIVE personalized tumor testing for Florida cancer patients

  This program will try a functional precision medicine and AI platform (xDRIVE) to help guide next treatment options for Florida patients with recurrent or refractory cancer, including children and people from underserved communities.

  Recruiting First Ascent Biomedical Inc. · Miami, Florida and 1 other locations · NCT07167381

• High-dose Topotecan treatment for recurrent retinoblastoma with vitreous seeds

  This study is testing whether high-dose Topotecan can help patients with recurrent retinoblastoma and vitreous seeds keep their eye while fighting the tumor.

  Recruiting Early Phase 1 Eye & ENT Hospital of Fudan University · Shanghai, China · NCT06972602

• CD19-targeted CAR-T (MC-1-50) for adults with refractory SLE

  This trial will try a rapid-manufactured CD19-directed CAR-T cell therapy called MC-1-50 in adults whose SLE has not responded to standard treatments.

  Recruiting at 2 sites Phase 1 Chongqing Precision Biotech Co., Ltd · Hefei, Anhui and 1 other locations · NCT06892145

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.